Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.

Renal function recovery after radical nephrectomy more likely in patients with lower preoperative EGFR

11 Apr 2018

Recovery to preoperative renal function occur within 2 years in a large proportion of patients after undergoing radical nephrectomy for kidney tumours, a recent study has confirmed, adding that recovery is more probable among those with a lower preoperative estimated glomerular filtration rate (EGFR).

Nearly half of the patients (45 percent) had recovered to the preoperative EGFR by 2 years following radical nephrectomy. Renal function recovery also differed based on preoperative renal function, such that those with a lower preoperative EGFR had greater chance of recovery.

Furthermore, female patients and those who had larger tumour size were likely to have a better chance of renal recovery function.

In this multicentre retrospective study, the investigators sought to confirm the findings from a previous single-institution study of 572 patients from Memorial Sloan Kettering Cancer Centre, in which they found that 49 percent of patients recovered to the preoperative EGFR within 2 years following radical nephrectomy for renal cell carcinoma.

A total of 1,928 patients were included in the study, which used data sourced from three independent centres. The primary outcome was postoperative recovery to the preoperative EGFR. The investigators analysed data using cumulative incidence and competing risks regression with death from any cause treated as a competing event.

A Japan study found that patients who had deteriorated renal function immediately after radical nephrectomy recovered over time, but those with chronic kidney disease, diabetes mellitus, cardiovascular disease and hypertension did not tend to recover renal function postoperatively. Independent risk factors for a >50-percent EGFR decrease included greater age and diabetes mellitus. [Int J Urol 2016;23:219-223]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.